Late last week in Morbidity and Mortality Weekly Report, authors from the Centers for Disease Control and Prevention (CDC) ...
Alignment with National Health Security Goals: GeoVax’s focus on U.S.-based vaccine production supports HHS’s priority of reducing dependency on foreign pharmaceutical supply chains, ensuring ...
(NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) ...
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...
Weight-loss drugs like Wegovy and Zepbound are proving incredibly lucrative, and analysts project this field will grow by leaps and bounds through the end of the decade. Viking Therapeutics is looking ...
4d
Hosted on MSNNovavax Lands Wall Street 'Buy' Rating After Q4 Results, Retail Bulls Eye More Upside On Sanofi PartnershipNovavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...
Novavax has significantly reduced its net loss in the fourth quarter of 2024 to $81.03 million ($0.51 per share), a ...
Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...
Novavax said it was eligible to receive royalties in high teens to low twenties percent on Sanofi sales, up to $350 million ...
5d
Hosted on MSNNovavax Retail Traders Stay Bullish Ahead Of Q4 Print Even As RFK Jr's HHS Leadership Causes RipplesNovavax Inc. shares climbed 2% on Wednesday and extended gains in after-hours trading, as retail investors maintained a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results